Ratios

		vs industry	vs history
P/B	10.15	FURX's P/B is ranked lower than 86% of the 429 Companies in the Global Business Services industry. ( Industry Median: 1.74 vs. FURX: 10.15 )	FURX' s 10-Year P/B Range Min: 0.64   Max: 9.86 Current: 10.15 0.64 9.86
P/S	5.15	FURX's P/S is ranked lower than 94% of the 429 Companies in the Global Business Services industry. ( Industry Median: 1.00 vs. FURX: 5.15 )	FURX' s 10-Year P/S Range Min: 4.39   Max: 99.79 Current: 5.15 4.39 99.79
EV-to-EBIT	-18.04	FURX's EV-to-EBIT is ranked higher than 83% of the 429 Companies in the Global Business Services industry. ( Industry Median: 13.30 vs. FURX: -18.04 )	FURX' s 10-Year EV-to-EBIT Range Min: 0   Max: 0 Current: -18.04

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	67.1	FURX's Price/Net Current Asset Value is ranked higher than 95% of the 429 Companies in the Global Business Services industry. ( Industry Median: 9.00 vs. FURX: 67.1 )	FURX' s 10-Year Price/Net Current Asset Value Range Min: 20.1   Max: 44 Current: 67.1 20.1 44
Price/Median PS Value	0.6	FURX's Price/Median PS Value is ranked higher than 53% of the 429 Companies in the Global Business Services industry. ( Industry Median: 0.90 vs. FURX: 0.6 )	FURX' s 10-Year Price/Median PS Value Range Min: 0.3   Max: 2.5 Current: 0.6 0.3 2.5

Business Description

Furiex Pharmaceuticals, Inc. is a Delaware Corporation. The Company is a drug development collaboration company that uses clinical development strategies to increase the value of partnered pharmaceutical assets and accelerate their development timelines. Its strategy is to invest in drug candidates that have a relatively straightforward path to regulatory approval and a large addressable market. Every drug candidate it reviews is subjected to its rigorous due diligence process by its team of experts who possess experience in all aspects of the drug development process. Currently, it has rights to several compounds in various stages of development and commercialization, including: Rights to royalties and regulatory and sales-based milestone payments from Takeda Pharmaceuticals Company Limited, for alogliptin and SYR-472. Takeda received regulatory and pricing approval in Japan during the second quarter of 2010 for alogliptin for the treatment of Type-2 diabetes. Takeda markets alogliptin in Japan under the name Nesina. Rights to royalties and regulatory and sales-based milestones from the collaboration with Alza Corporation, an affiliate of Janssen Pharmaceutica, N.V., for Priligy, the first approved treatment in the world for premature ejaculation. Priligy is currently marketed in 15 countries in Europe, Asia-Pacific and Latin America. A compound licensed from Janssen, (an affiliate of Johnson & Johnson), in November 2009 that is a mu opioid receptor agonist and delta opioid receptor antagonist, which it call MuDelta, for the treatment of diarrhea-predominant irritable bowel syndrome. It completed a Phase II Proof-of-Concept clinical trial during 2011 which demonstrated that MuDelta has a favorable efficacy and safety profile. It has two Phase III-ready products in clinical development, with exclusive license rights to both products: MuDelta and JNJ-Q2. In addition it have one compound in Phase III development with a collaborator, SYR-472, and two compounds that are commercialized by collaborators, for which it are eligible to receive regulatory milestone payments plus worldwide sales royalty and milestone payments. These compounds, Nesina and Priligy, are currently marketed outside of the United States, and it has no further development obligations for any of these three compounds. A fluoroquinolone antibiotic licensed from Janssen in November 2009, which it calls JNJ-Q2, for the treatment of acute bacterial skin and skin structure infections, such as abscesses that occur deep in the skin layers, and respiratory infections. The manufacturing, testing, labeling, approval and storage of the Company's products are subject to rigorous regulation by numerous governmental authorities in the United States and other countries at the federal, state and local level, including the FDA.
Company Website
SEC Reports

Industry:	Business Services
Compare:
Traded in other countries:	FUF.Germany

» More Articles for FURX

Headlines

Articles On GuruFocus.com

Personalized Checklist